Extended Data Fig. 4: Extended T cell data.
From: IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma

(a) Correlation of fold change in lymphocyte count measured on routine hospital bloods (as per Lymphocyte Stability) versus % change in cell subset as measured using flow-cytometry at the same timepoint. From left: right; % all T cells in PBMC, % T Effector Memory, % Naïve T cells; P value from Spearman rank test, dotted lines reflect fitted linear model, shaded area the 95% Confidence Interval, n = 40. (b) Correlation of CD8+ T cell expression of SH3BGRL2 versus the naïve marker CD27 in healthy donors (left facet) and patient samples (right facet); Spearman rank test, shaded area reflects 95% Confidence Interval of fitted linear model, P interaction with status <0.001, n = 67 controls, n = 326 patient C1/C2 samples. (c) GOBP pathway analysis of genes upregulated in CD8+ T cells in carriers of risk allele (as depicted in Fig. 4b), one-tailed hypergeometric test. (d) GOBP pathway analysis of genes anti-correlated in patient CD8+ T cells with increasing B cell IL7 expression from same blood samples, having corrected for rs16906115 status, one-tailed hypergeometric test. e) GOBP pathway analysis of genes anti-correlated in patient CD8+ T cells with increasing B cell IL7 expression in non-carriers of risk allele only, one-tailed hypergeometric test.